Anti-infective use in children and pregnancy: current deficiencies and future challenges.

There are a number of challenges to using anti-infective agents in children and pregnant women. There is limited understanding of the altered pharmacokinetics of anti-infectives in these populations and as a result, optimized dosing regimens are yet to be established. The potential adverse effects of the drug on pregnancy outcome and the developing foetus is a major consideration, and the long term implications of drug side effects must be taken into account when drug exposure occurs early in life. These factors hinder research and licensing of new anti-infective drugs in these populations. We describe the current deficiencies and future challenges of anti-infective use in children and pregnant women, providing specific examples.

[1]  B. Guglielmo,et al.  Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.

[2]  B. Pasternak,et al.  Use of oral fluconazole during pregnancy and the risk of birth defects. , 2013, The New England journal of medicine.

[3]  A. Riordan,et al.  Vancomycin dosing in children: what is the question? , 2013, Archives of Disease in Childhood.

[4]  A. Shennan,et al.  The challenges of licensing drugs for use in pregnancy , 2013, Expert opinion on pharmacotherapy.

[5]  Mehul Dhorda,et al.  Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda , 2013, Antimicrobial Agents and Chemotherapy.

[6]  C. Rayner,et al.  Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies , 2013, Antimicrobial Agents and Chemotherapy.

[7]  C. Staatz,et al.  Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis , 2013, Clinical Pharmacokinetics.

[8]  Talene A. Metjian,et al.  The Use of Intravenous Colistin Among Children in the United States: Results From a Multicenter, Case Series , 2013, The Pediatric infectious disease journal.

[9]  A. Zolopa,et al.  Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients , 2012 .

[10]  Kassoum Kayentao,et al.  Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review , 2012, Malaria Journal.

[11]  E. Alp,et al.  Old agent, new experience: colistin use in the paediatric Intensive Care Unit--a multicentre study. , 2012, International journal of antimicrobial agents.

[12]  U. d’Alessandro,et al.  A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy , 2012, Malaria Journal.

[13]  M. Kamya,et al.  Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study , 2012, Journal of the International AIDS Society.

[14]  J. Korth-Bradley,et al.  Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. , 2012, Clinical therapeutics.

[15]  J. Roberts,et al.  The Clinical Relevance of Plasma Protein Binding Changes , 2012, Clinical Pharmacokinetics.

[16]  O. Dawod,et al.  Effect of quinine therapy on plasma glucose and plasma insulin levels in pregnant women infected with Plasmodium falciparum malaria in Gezira state. , 2011, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[17]  Thomas M. English,et al.  Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients , 2011, The Annals of pharmacotherapy.

[18]  C. Oudin,et al.  Vancomycin prescription in neonates and young infants: toward a simplified dosage , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[19]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Nosten,et al.  Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. , 2010, The Lancet. Infectious diseases.

[21]  S. Talungchit,et al.  Effects of long-term use of HAART on oral health status of HIV-infected subjects. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[22]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.

[23]  Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. , 2010, MMWR. Morbidity and mortality weekly report.

[24]  K. Stoltze,et al.  Hyposalivation, xerostomia and oral health status of HIV-infected subjects in Thailand before HAART era. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[25]  Organización Mundial de la Salud Guidelines for the treatment of malaria , 2010 .

[26]  M. Falagas,et al.  Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. , 2009, International journal of antimicrobial agents.

[27]  C. Dollfus,et al.  Correction of facial lipoatrophy using autologous fat transplants in HIV‐infected adolescents , 2009, HIV medicine.

[28]  Nawal M. Nour,et al.  Malaria and pregnancy: a global health perspective. , 2009, Reviews in obstetrics & gynecology.

[29]  F. Nosten,et al.  The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria , 2009, European Journal of Clinical Pharmacology.

[30]  H. Sørensen,et al.  Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. , 2008, The Journal of antimicrobial chemotherapy.

[31]  Paige L. Williams,et al.  Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  F. Nosten,et al.  Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug‐resistant falciparum malaria , 2007, Tropical medicine & international health : TM & IH.

[33]  L. Gustafsson,et al.  Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria , 2007, Journal of clinical pharmacy and therapeutics.

[34]  J. Massie,et al.  Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis , 2006, Journal of paediatrics and child health.

[35]  C. Whitty,et al.  REVIEW: Malaria in pregnancy , 2005, BJOG : an international journal of obstetrics and gynaecology.

[36]  M. J. García-Miguel,et al.  Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children , 2005, European Journal of Pediatrics.

[37]  Yusuke Tanigawara,et al.  MICROMEDEX® Healthcare Series , 2004 .

[38]  Azza,et al.  Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe , 2004, AIDS.

[39]  J. N. van den Anker,et al.  Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.

[40]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[41]  J. Niebyl Antibiotics and Other Anti-infective Agents in Pregnancy and Lactation , 2003, American journal of perinatology.

[42]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[43]  G. McComsey Metabolic complications of antiretroviral therapy in children , 2003, The Pediatric infectious disease journal.

[44]  C. Kozinetz,et al.  Lipodystrophy syndrome in human immunodeficiency virus-infected children , 2002, The Pediatric infectious disease journal.

[45]  J. Rotschafer,et al.  What Do We Really Know About Antibiotic Pharmacodynamics? , 2001, Pharmacotherapy.

[46]  S. Krudsood,et al.  A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. , 2001, The American journal of tropical medicine and hygiene.

[47]  H. Sørensen,et al.  Risk of malformations and other outcomes in children exposed to fluconazole in utero. , 1999, British journal of clinical pharmacology.

[48]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[49]  G. Koren,et al.  Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance , 1997, Clinical pharmacokinetics.

[50]  D. Bartley,et al.  Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. , 1997, American journal of medical genetics.

[51]  J. Abraham,et al.  Fluconazole-induced congenital anomalies in three infants. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  P. Routledge Pharmacokinetics in children. , 1994, The Journal of antimicrobial chemotherapy.

[53]  J. D. De MELLO MALARIA IN PREGNANCY , 1983, The Lancet.